PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)
Patient Derived Xenograft Model Market, By Model Type (Cell line derived models, Patient derived organoids, Genetically engineered models and Others (Primary cell derived models, cell processed models etc.)), By Implantation Method (Subcutaneous Implantation, Orthopedic Implantation and Others), By Tumor Type (Blood Cancer Models, Solid Tumor Models, Pediatric Tumor Models, Other Rare Tumor Models, Combination PDX Models, Custom PDX Models, Others), By Application (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model and Other Tumor Model), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Patient Derived Xenograft Model Market Regional Insights:
North America is expected to be the largest market for Patient Derived Xenograft Model Market during the forecast period, accounting for over 34.2% of the market share in 2022. The growth of the market in North America is attributed to the high adoption rate of PDX models in preclinical and translational research, increasing government funding for cancer research, and presence of leading PDX model providers in the region.
The Europe market is expected to be the second-largest market for Patient Derived Xenograft Model Market, accounting for over 27.8%% of the market share in 2022. The growth of the market in Europe is attributed to the rising incidence of cancer, well-developed healthcare research infrastructure, and increasing focus on personalized medicine in the region.
The Asia Pacific market is expected to be the fastest-growing market for Patient Derived Xenograft Model Market, with a CAGR of over 21.7% during the forecast period. The growth of the market in Asia Pacific is attributed to the improving R&D infrastructure, increasing pharmaceutical R&D investments, and growing focus on developing better cancer therapies in the region.
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa
U.S.: 
U.K. : 
India : 
